Ondansetron Injection USP -(Preservative Free) 2 mg (Ondansetron (Ondansetron Hydrochloride Dihydrate) SOLUTION) 2 MG

Ondansetron Injection USP is a preservative-free solution used to prevent nausea and vomiting. This 2 mg intravenous solution is manufactured by Sandoz Canada Incorporated.

Strength

2 MG

Pack Size

2/4MLVIALS

Manufacturer / TM Owner

SANDOZ CANADA INCORPORATED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ondansetron Injection USP is commonly used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, or surgery. It works by blocking serotonin receptors in the brain, which helps to reduce these symptoms. Ondansetron is often administered intravenously for quick relief.

Side Effects

Ondansetron Injection USP may cause common side effects such as headache, constipation, and dizziness. Some users may also experience fatigue or mild diarrhea. These effects are usually temporary and subside as the body adjusts to the medication.

Precautions & Warnings

Ondansetron Injection USP should be handled with care, ensuring proper storage and administration. It is important to follow medical guidance for usage, especially for those with a history of heart conditions or low potassium levels. Always inform healthcare providers of any allergies or current medications.

Avoid Interactions

Ondansetron Injection USP may interact with certain medications, including apomorphine, which can cause a severe drop in blood pressure. It is also important to avoid alcohol while using this medication, as it can increase the risk of side effects. Always consult a healthcare provider before combining ondansetron with other medications.

Frequently Asked Questions

Ondansetron Injection USP is used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, or surgery.

Ondansetron Injection USP is typically administered intravenously by a healthcare professional.

Common side effects may include headache, constipation, dizziness, fatigue, and mild diarrhea.

Ondansetron may interact with certain medications, so it is important to consult a healthcare provider before combining it with other drugs.

Ondansetron should be used with caution in individuals with heart conditions or low potassium levels, and always under medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.